Platinum Investment Management Ltd. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 90.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,800 shares of the company’s stock after selling 323,527 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Johnson & Johnson were worth $4,264,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in JNJ. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $124,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $177,000. Finally, Lenox Wealth Management Inc. lifted its holdings in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after buying an additional 24 shares during the period. 67.35% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) opened at $132.63 on Tuesday. The stock has a market capitalization of $358,972.31, a PE ratio of 18.33, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.19% of the stock is currently owned by corporate insiders.
Several brokerages have recently commented on JNJ. Citigroup reduced their target price on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a report on Thursday, January 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Monday, February 26th. Finally, Stifel Nicolaus upped their target price on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $146.26.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.